Cargando…

LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis

Background: Crizotinib is a microtubule-related protein-4-anaplastic lymphoma kinase (EML4-ALK) multi-target tyrosine kinase inhibitor applied in the treatment of ALK-rearranged NSCLC. However, the specific molecular mechanism underlying its therapeutic effect remains unclear. Therefore, the purpose...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Meiling, Wang, Qian, Ke, Zihao, Liu, Yijing, Guo, Huijin, Fang, Shencun, Lu, Kaihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8497803/
https://www.ncbi.nlm.nih.gov/pubmed/34630126
http://dx.doi.org/10.3389/fphar.2021.759267

Ejemplares similares